What drove the big move in 4506.T stock today?

The move followed a government panel endorsement of Sumitomo Pharma’s iPS-derived Parkinson’s therapy. That news concentrated trading and triggered heavy volume and a sharp intraday price move.

What is Meyka AI’s short-term forecast for 4506.T stock?

Meyka AI's forecast model projects a monthly target of JPY 2,368.14, implying about **-4.34%** from the JPY 2,475.50 close. Forecasts are model-based projections and not guarantees.

Is 4506.T stock undervalued after the drop?

Valuation metrics show a low PE of **7.53** and strong ROE, which suggests value by some measures. Assess pipeline risk, regulatory outcomes, and debt levels before concluding undervaluation.

How should active traders approach 4506.T stock now?

Active traders should use tight risk controls and watch liquidity. Key intraday support sits near JPY 2,446.50. Monitor news wires and volume spikes for trade signals.

JP Stocks

4506.T Sumitomo Pharma (JPX) down 15.44% Feb 2026: iPS panel drives heavy volume

ByHuzaifa Zahoor February 20, 2026February 20, 2026

4506.T stock led Tokyo trading at market close after Sumitomo Pharma Co., Ltd. (JPX) fell 15.44% to JPY 2,475.50 on 20 Feb 2026. Volume surged to 57,229,700 shares, far above the 50-day average of JPY 2,402.22 (price avg 50). The move followed a government panel endorsement of the company’s iPS cell-derived Parkinson’s therapy and sparked the day’s heaviest flows. We review the trading action, fundamentals, technicals, and model forecasts to frame next steps for active traders and longer-term investors.